Advanced Prostate Cancer Therapeutics
1. Orgovyx patent expiration
Treatment: Treatment of adult patients with advanced prostate cancer; Treatment of adult patients with Read More
ORGOVYX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7300935 | SUMITOMO PHARMA AM | Thienopyrimidine compounds and use thereof |
Jan, 2029
(3 years from now) | |
| US11795178 | SUMITOMO PHARMA AM | Compositions of thienopyrimidine derivatives |
Sep, 2033
(7 years from now) | |
| US12325714 | SUMITOMO PHARMA AM | Compositions of thienopyrimidine derivatives |
Sep, 2033
(7 years from now) | |
| US8058280 | SUMITOMO PHARMA AM | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2026
(19 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11583526 | SUMITOMO PHARMA AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US8735401 | SUMITOMO PHARMA AM | Thienopyrimidine compounds and use thereof |
Feb, 2024
(1 year, 11 months ago) | |
| US12336990 | SUMITOMO PHARMA AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US12144809 | SUMITOMO PHARMA AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US10449191 | SUMITOMO PHARMA AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US10786501 | SUMITOMO PHARMA AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US12097198 | SUMITOMO PHARMA AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US10350170 | SUMITOMO PHARMA AM | Solid preparation |
Feb, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 18 December, 2020
Dosage: TABLET
More Information on Dosage
ORGOVYX family patents
2. Plenaxis patent expiration
Treatment: Use in the treatment of men with advanced symptomatic prostate cancer
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5968895 | SPECIALITY EUROPEAN | Pharmaceutical formulations for sustained drug delivery |
Dec, 2016
(9 years ago) | |
| US6455499 | SPECIALITY EUROPEAN | Methods for treating disorders associated with LHRH activity |
Jun, 2015
(10 years ago) | |
| US6180608 | SPECIALITY EUROPEAN | Pharmaceutical formulations for sustained drug delivery |
Dec, 2016
(9 years ago) | |
| US5843901 | SPECIALITY EUROPEAN | LHRH antagonist peptides |
Dec, 2015
(10 years ago) | |
| US6423686 | SPECIALITY EUROPEAN | LHRH antagonist peptides |
Jun, 2015
(10 years ago) | |
| US6699833 | SPECIALITY EUROPEAN | Pharmaceutical formulations for sustained drug delivery |
Dec, 2016
(9 years ago) | |
Drugs and Companies using ABARELIX ingredient
Market Authorisation Date: 25 November, 2003
Dosage: INJECTABLE
More Information on Dosage
PLENAXIS family patents
3. Vanrafia patent
expiration
Treatment: Treatment of primary immunoglobulin a nephropathy (igan)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12121509 | NOVARTIS | Methods of improving renal function |
Dec, 2040
(14 years from now) | |
| US11998526 | NOVARTIS | Methods of improving renal function |
Dec, 2040
(14 years from now) | |
| US11874283 | NOVARTIS | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
Feb, 2032
(6 years from now) | |
| US11491137 | NOVARTIS | Methods of improving renal function |
Dec, 2040
(14 years from now) | |
| US9364458 | NOVARTIS | Stabilized pharmaceutical dosage forms comprising atrasentan |
Jul, 2034
(8 years from now) | |
| US8623819 | NOVARTIS | Therapy for complications of diabetes |
Aug, 2028
(2 years from now) | |
| US12370174 | NOVARTIS | NA |
Dec, 2040
(14 years from now) | |
| US10016393 | NOVARTIS | Stabilized pharmaceutical dosage forms comprising atrasentan |
Jul, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2030 |
Drugs and Companies using ATRASENTAN HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2029
Market Authorisation Date: 02 April, 2025
Dosage: TABLET
More Information on Dosage
VANRAFIA family patents